DANIEL B. SOLAND - 24 Jan 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Role: CHIEF OPERATING OFFICER
Signature: /s/ Daniel B. Soland
Issuer symbol: N/A
Transactions as of: 24 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2022, 19:42:27 UTC
Previous filing: 01 Oct 2021
Next filing: 04 Apr 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDRA	Stock Option (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	24 Jan 2022	Common Stock	25,000	$0.5746	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Content

The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.